Lakewood-Amedex, Inc. to Present at 2018 BIO CEO & Investor Conference

Thursday, February 8, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

SARASOTA, Fla., Feb. 8, 2018 /PRNewswire/ -- Lakewood-Amedex, Inc., a leading developer of novel anti-infective pharmaceuticals,

today announced that it will present at the 2018 BIO CEO & Investor Conference, held February 12-13, 2018, in New York City.

Steve Parkinson, President

and CEO of Lakewood-Amedex, plans to present data on the Company's lead therapeutic candidate, Nu-3, a topically applied antimicrobial which recently completed a Phase 1/2a clinical trial in patients with infected diabetic foot ulcers (iDFU). The presentation will also highlight the Company's second drug candidate, Nu-8, which Lakewood-Amedex anticipates advancing into preclinical IND-enabling studies following positive pre-IND written communications with the FDA. Nu-8 will be developed for the treatment of complicated urinary tract infections (cUTI) that are currently treated with systemic orally delivered antibiotics.

Lakewood-Amedex Presentation Details:Date: Tuesday, February 13, 2018 Time: 9:45 AM (Eastern Time)Location: New York Marriott Marquis, Gilbert Room

An audio webcast will be accessible for 90 days following the presentation via the following link: http://www.veracast.com/webcasts/bio/ceoinvestor2018/58208329358.cfm 

About Lakewood-Amedex, Inc.Lakewood-Amedex is a clinical stage pharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class antimicrobial compounds. The Company's products and technology are covered by an extensive patent portfolio consisting of over 100 granted and/or issued patents and 4 pending patent applications covering many major pharmaceutical markets. The Company's lead therapeutic candidate is a novel synthetic broad-spectrum antimicrobial proven to be effective in killing a wide range of Gram-positive, Gram-negative and antibiotic-resistant bacteria and has recently completed a Phase 1/2a clinical trial in patients with infected diabetic foot ulcers (iDFU).

Contacts:Tiberend Strategic Advisors, Inc.Jonathon Brzezinski, Ph.D. (investors)jbrzezinski@tiberend.com (212) 375-2681

Tiberend Strategic Advisors, Inc.David Schemelia (media)dschemelia@tiberend.com (212) 375-2686

Cision View original content:http://www.prnewswire.com/news-releases/lakewood-amedex-inc-to-present-at-2018-bio-ceo--investor-conference-300595543.html

SOURCE Lakewood-Amedex, Inc.

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store